- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07345910
Miljö, patogener och värdinteraktioner vid melioidos (DeEPH)
Avkodning av triaden: samspelet mellan miljö, patogen och värd vid melioidos (DeEPH)
This is a longitudinal, multicentre observational study conducted across three established microbiology units integrated within hospital and community health systems in Thailand, Lao PDR, and Cambodia.
The hospital cohort will enroll approximately1,000 patients with positive melioidosis. Participants will be followed at six time points from admission through one year (post-discharge) to capture acute and recovery-phase outcomes, with clinical data collected on demographics, comorbidities, exposures, treatment, adherence, and outcomes.
For each confirmed case, a healthy control will be recruited within two weeks and matched by age, sex, and village of residence. Controls with no symptoms or history of melioidosis will provide a single blood sample at enrolment and will be followed by telephone at 6 and 12 months.
In addition to hospital-based surveillance, a high-risk community in northern Ubon Ratchathani-referred to as the Sandbox Village-will be intensively monitored to capture subclinical infections and to assess environmental factors influencing disease acquisition.
This study is funded by the Wellcome Trust. The grant reference number is 323077/Z/24/Z
Studieöversikt
Status
Betingelser
Detaljerad beskrivning
This is a longitudinal, multicentre observational study conducted across three established microbiology units integrated within hospital and community health systems:
- Sunpasitthiprasong Hospital, Ubon Ratchathani, Thailand (MORU);
- Mahosot Hospital, Vientiane, Lao PDR (LOMWRU); and
- Angkor Hospital for Children, Siem Reap, Cambodia (COMRU).
In addition to hospital-based surveillance, a high-risk community in northern Ubon Ratchathani-referred to as the Sandbox Village-will be intensively monitored to capture subclinical infections and to assess environmental factors influencing disease acquisition.
Participant Recruitment and Follow-up
Hospital cohort:
Patients with melioidosis will be recruited at all three hospital sites. The study plans to recruit 1,000 patients, who will be followed longitudinally at six time points: Day 0 (admission), Days 3 and 7 (acute phase), and Days 30, 180, and 365 (recovery phase).
Clinical data collected will include demographic characteristics, underlying comorbidities, environmental exposures, lifestyle and behavioural factors, treatment history, patient-reported medication adherence, and follow-up outcomes.
Healthy controls:
Each patient will be matched with a healthy control recruited within two weeks of diagnosis, based on age, sex, and village of residence. Controls will have no current symptoms or prior history of melioidosis. They will provide a single blood sample at enrolment for DNA extraction and antibody profiling and will be followed up by telephone on Days 180 and 365.
Community cohort:
To complement hospital-based data and to identify subclinical infections, intensive community surveillance will be conducted in the Sandbox Village, a high-incidence area within the Ubon Ratchathani region. All residents (approximately 400 individuals) will be enrolled. DNA samples will be collected at baseline, and serum samples will be obtained every two months over a 42-month period, either at participants' homes or at a central village location, to measure antibody responses to Burkholderia pseudomallei as a proxy for exposure.
Community cohort:
To complement hospital-based data and to identify subclinical infections, intensive community surveillance will be conducted in the Sandbox Village, a high-incidence area within the Ubon Ratchathani region. All residents (approximately 400 individuals) will be enrolled. DNA samples will be collected at baseline, and serum samples will be obtained every two months over a 42-month period, either at participants' homes or at a central village location, to measure antibody responses to Burkholderia pseudomallei as a proxy for exposure.
Studietyp
Inskrivning (Beräknad)
Kontakter och platser
Studiekontakt
- Namn: Kamolchanok Claire Chewapreecha, PhD
- Telefonnummer: 662 203 6333
- E-post: claire@tropmedres.ac
Studieorter
-
-
-
Siem Reap, Kambodja
- Har inte rekryterat ännu
- Cambodia-Oxford Medical Research Unit (COMRU)
-
Kontakt:
- Paul Turner, MD
- E-post: Pault@tropmedres.ac
-
-
-
-
-
Vientiane, Laos
- Har inte rekryterat ännu
- Lao-Oxford-Mahosot Hospital Wellcome Trust Research Unit (LOMWRU)
-
Kontakt:
- Elizabeth Ashley, MD
- E-post: Elizabeth.Ashley@tropmedres.ac
-
-
-
-
-
Ubon Ratchathani, Thailand
- Rekrytering
- Sunpasitthiprosong Hospital
-
Kontakt:
- Kamolchanok C Chewapreecha, PhD
- Telefonnummer: 022036333
- E-post: claire@tropmedres.ac
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Melioidosis patients:
Patients confirmed to have melioidosis.
Healthy controls:
For each confirmed melioidosis case, a healthy control-defined as having no current fever, no evidence of soft tissue infection, and no prior history of melioidosis-will be recruited from satellite blood bank donors within approximately two weeks of case identification. Controls will be matched by age (±5 years), sex, and village of residence.
Sandbox Village residents:
All residents of the Sandbox Village, a high-risk area for melioidosis, will be enrolled to monitor disease progression and to evaluate the impact of improved water sanitation.
Beskrivning
Inclusion criteria for melioidosis patients:
- Age ≥20 years
- Positive for Burkholderia pseudomallei from any clinical samples
- Resident of the study area for at least two years, including the follow-up period
- Willing to participate and give informed consent.
Inclusion criteria for healthy controls:
- Age ≥20 years
- Currently healthy as judged by study doctor
- Resident of the study area for at least two years, including the follow-up period
- Willing to participate and give informed consent.
Inclusion criteria for sandbox residents:
- Age ≥20 years
- Resident of the study area for at least two years, including the follow-up period
- Willing to participate and give informed consent.
Exclusion criteria for melioidosis patients:
- Current tuberculosis (TB) or TB treatment within the past six months
- Documented HIV infection or use of immunosuppressive therapy in the past 12 months
Exclusion criteria for healthy controls:
- History of melioidosis
- Significant acute illness
- Current fever or soft tissue infection
Exclusion criteria for sandbox residents
-N/A
Studieplan
Hur är studien utformad?
Designdetaljer
- Observationsmodeller: COHORT
- Tidsperspektiv: PROSPECTIVE
Kohorter och interventioner
Grupp / Kohort |
|---|
|
Melioidosis patients
Patients confirmed to have melioidosis |
|
Healthy controls
Healthy controls will be enrolled for each confirmed melioidosis case. A healthy control is defined as an individual with no current fever, no evidence of soft tissue infection, and no prior history of melioidosis. Controls will be recruited within approximately two weeks of case identification and will be matched to cases by age (±5 years), sex, and village of residence. |
|
Sandbox village cohort
All residents of the Sandbox Village, a high-risk area for melioidosis, will be enrolled to monitor disease progression and to evaluate the impact of improved water sanitation. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Utveckling av melioidos efter exponering, utvärderat bland melioidosfall
Tidsram: 365 dagar
|
365 dagar
|
|
Utveckling av melioidos efter exponering, bedömd bland friska kontroller
Tidsram: 365 dagar
|
365 dagar
|
|
Utveckling av melioidos efter exponering, utvärderat bland invånare i Sandbox Village
Tidsram: 3,5 år
|
3,5 år
|
|
Dödlighet under den akuta fasen av infektion bland individer med melioidos (melioidosfall).
Tidsram: 365 dagar
|
365 dagar
|
|
Antal återinläggningar på sjukhus efter utskrivning bland personer med melioidos (melioidosfall).
Tidsram: 365 dagar
|
365 dagar
|
Sekundära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Förändringar i sjukdomsutveckling efter exponering i samband med interaktioner mellan miljöförändringar.
Tidsram: 3,5 år
|
3,5 år
|
|
Förändringar i dödligheten under den akuta fasen av infektion efter exponering i samband med interaktioner mellan miljömässiga modifieringar.
Tidsram: 365 dagar
|
365 dagar
|
|
Förändringar i återinläggning på sjukhus efter återhämtning i samband med interaktioner mellan miljöanpassningar.
Tidsram: 365 dagar
|
365 dagar
|
|
Förändringar i sjukdomsutvecklingen efter exponering i samband med interaktioner mellan kliniska hanteringsfaktorer.
Tidsram: 365 dagar
|
365 dagar
|
|
Förändringar i dödlighet under den akuta infektionsfasen efter exponering som är associerade med interaktioner mellan kliniska behandlingsfaktorer.
Tidsram: 365 dagar
|
365 dagar
|
|
Förändringar i återinläggning på sjukhus efter återhämtning i samband med interaktioner mellan kliniska behandlingsfaktorer.
Tidsram: 365 dagar
|
365 dagar
|
|
Förändringar i sjukdomsutveckling efter exponering associerad med interaktioner som involverar genetisk mottaglighet.
Tidsram: 365 dagar
|
365 dagar
|
|
Förändringar i dödligheten under den akuta fasen av infektion efter exponering associerad med interaktioner som involverar genetisk mottaglighet.
Tidsram: 365 dagar
|
365 dagar
|
|
Förändringar i återinläggning på sjukhus efter återhämtning associerade med interaktioner som involverar genetisk mottaglighet.
Tidsram: 365 dagar
|
365 dagar
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Kamolchanok Claire Chewapreecha, PhD, Mahidol Oxford Tropical Research Unit
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- MEL25001
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
The study outputs, including genomic and transcriptomic data and associated metadata, will be valuable for future research. In compliance with the Wellcome Trust's open data policies and to encourage reproducibility, data will be deposited in two repositories:
Human genomic and transcriptomic data: European Genome-Phenome Archive (EGA), under managed access
Bacterial genomic data: European Nucleotide Archive (ENA), open access
Pseudonymised metadata, including participant demographics and microbiological findings, will be shared with qualified researchers in accordance with the General Data Protection Regulation (GDPR). No personally identifiable information will be shared, and participants will not be identifiable from any released data.
IPD-delning som stöder informationstyp
- STUDY_PROTOCOL
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .